levetiracetam (add-on)
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Status Epilepticus
Conditions
Status Epilepticus
Trial Timeline
Oct 1, 2006 → Apr 1, 2008
NCT ID
NCT00362141About levetiracetam (add-on)
levetiracetam (add-on) is a phase 2 stage product being developed by UCB for Status Epilepticus. The current trial status is unknown. This product is registered under clinical trial identifier NCT00362141. Target conditions include Status Epilepticus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00362141 | Phase 2 | UNKNOWN |
Competing Products
9 competing products in Status Epilepticus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGM097 | Novartis | Phase 1 | 33 |
| BVS857 | Novartis | Phase 2 | 52 |
| Lorazepam | Pfizer | Phase 3 | 76 |
| Lorazepam | Pfizer | Pre-clinical | 22 |
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Phase 1 | 30 |
| SAGE-547 | Supernus Pharmaceuticals | Pre-clinical | 18 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |